International scientific community gathers in Valencia for the 9th ESWI Conference on Influenza, COVID-19, and RSV
Since it was established 30 years ago, the European Scientific Working Group on Influenza and other Acute Respiratory Viruses (ESWI) is hosting the 9TH ESWI Influenza Conference
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
This study demonstrates durable yet compartmentalised nasal IgA and plasma antibody responses to SARSCoV-2 after infection and subsequent vaccination.
Policy & Recommendations
The role of EU manufacturing capacity in future health crisis
A study assessing scientific, engineering, legal and economic considerations of flexible EU manufacturing and innovation of medical countermeasures for serious cross-border threats to health
Policy & Recommendations
European Commission authorises first vaccine to protect older adults from RSV infection
The EC has authorised Arexvy, the first vaccine to protect adults aged 60 years and older, against RSV. This decision marks an important step and has been particularly awaited in light of the increased RSV infections in the EU last winter.
Influenza Vaccines: What Does the mRNA Platform Have to Offer?
Are you up to date about current developments in influenza vaccines with the messenger RNA (mRNA) platform?
Algorithm for Optimised mRNA Design Improves Stability and Immunogenicity
mRNA vaccines are being used to contain COVID-19, but still suffer from the critical limitation of mRNA instability and degradation, which is a major obstacle in the storage, distribution, and efficacy of the vaccine products.
ECDC on Air podcast: The solidarity of Vaccination
European Immunization Week is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunisation for the general health and well-being of the European and wider population.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Whether vaccination during pregnancy could reduce the burden of RSV associated lower respiratory tract illness in newborns and infants is uncertain.
How mRNA technology is improving the flu Shot: The Big Take podcast by Bloomberg
It’s estimated that half a million or more people around the world die of influenza each year. And many of these deaths could be prevented with a highly effective, widely used flu shot.
United in Protection: vaccination is a show of solidarity!
Ahead of European Immunisation Week (EIW), taking place from 23 to 29 April 2023, Isabel de la Mata -principal advisor for Health and Crisis Management at the European Commission- talks about the benefits of lifelong vaccination
Improving Adult Vaccination Policy in Long-Term Care Settings. Technical Report.
With the World Immunization Week coming up, IFA has produced a study to deliver critical baseline data to help inform technical guidelines, as well as governmental and civil society dialogue and policy actions, to protect the health of LTC residents.